Many Life Sciences organizations perform clinical development both internally with their own teams and also by leveraging Clinical Research Organizations (CRO) providers.  Depending on the size of the Life Sciences company, this means that they may have one or more of the following systems: Clinical Trial Management Systems (CTMS), Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), e-Diary Patient Reported Outcome (ePRO), Interactive Voice and Web Response System…

The current budgetary and economic crises facing the United States mandates that we must maximize the impact of technology transfer in both the public and private sectors if we are to remain competitive in the 21st century. This is a topic that President Obama has outlined in a recent Presidential Policy Memoranda addressed to the federal laboratory system, and in the Administration challenge for our research universities to commit themselves to fully support commercializing technologies…

Product development in the Life Sciences industry is generally a risky business…for every 25,000 compounds tested in the laboratory, 25 will enter clinical trials, 5 will be approved by regulatory authorities, and only 1 is likely to recoup the investment made. 

To see how the industry and the risks involved have become so daunting, let’s examine what has occurred over the past 10 years:

1. Lack of Incentive to Invest: 
   • Biotech: A cumulative operating income…